<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">12703</article-id><article-id pub-id-type="doi">10.7554/eLife.12703</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Mouse models of human <italic>PIK3CA</italic>-related brain overgrowth have acutely treatable epilepsy</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-32244"><name><surname>Roy</surname><given-names>Achira</given-names></name><aff><institution content-type="dept">Center for Integrative Brain Research</institution>, <institution>Seattle Children's Research Institute</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32245"><name><surname>Skibo</surname><given-names>Jonathan</given-names></name><aff><institution content-type="dept">Center for Integrative Brain Research</institution>, <institution>Seattle Children's Research Institute</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32246"><name><surname>Kalume</surname><given-names>Franck</given-names></name><aff><institution content-type="dept">Center for Integrative Brain Research</institution>, <institution>Seattle Children's Research Institute</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32247"><name><surname>Ni</surname><given-names>Jing</given-names></name><aff><institution content-type="dept">Department of Cancer biology</institution>, <institution>Dana Farber Cancer Institute</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32248"><name><surname>Rankin</surname><given-names>Sherri</given-names></name><aff><institution content-type="dept">Department of Developmental Neurobiology</institution>, <institution>St. Jude Children's Research Hospital</institution>, <addr-line><named-content content-type="city">Memphis</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32249"><name><surname>Lu</surname><given-names>Yiling</given-names></name><aff><institution>The University of Texas MD Anderson Cancer Center</institution>, <addr-line><named-content content-type="city">Houston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32250"><name><surname>Dobyns</surname><given-names>William B</given-names></name><aff><institution content-type="dept">Center for Integrative Brain Research</institution>, <institution>Seattle Children's Research Institute</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15958"><name><surname>Mills</surname><given-names>Gordon B</given-names></name><aff><institution>The University of Texas MD Anderson Cancer Center</institution>, <addr-line><named-content content-type="city">Houston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-8531"><name><surname>Zhao</surname><given-names>Jean J</given-names></name><aff><institution content-type="dept">Department of Cancer Biology</institution>, <institution>Dana Farber Cancer Institute</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-5144"><name><surname>Baker</surname><given-names>Suzanne J</given-names></name><aff><institution content-type="dept">Department of Developmental Neurobiology</institution>, <institution>St. Jude Children's Research Hospital</institution>, <addr-line><named-content content-type="city">Memphis</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-7008"><name><surname>Millen</surname><given-names>Kathleen J</given-names></name><aff><institution content-type="dept">Center for Integrative Brain Research</institution>, <institution>Seattle Children's Research Institute</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country><email>kathleen.millen@seattlechildrens.org</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1146"><name><surname>Morrison</surname><given-names>Sean J</given-names></name><role>Reviewing editor</role><aff><institution>Howard Hughes Medical Institute, University of Texas Southwestern Medical Center</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>03</day><month>12</month><year>2015</year></pub-date><volume>4</volume><elocation-id>e12703</elocation-id><supplementary-material><ext-link xlink:href="elife-12703-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>29</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2015</year></date></history><permissions><copyright-statement>Â© 2015, Roy et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Roy et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Mutations in the catalytic subunit of phosphoinositide 3-kinase (<italic>PIK3CA</italic>) and other PI3K-AKT pathway components have been associated with cancer and a wide spectrum of brain and body overgrowth. In the brain, the phenotypic spectrum of <italic>PIK3CA</italic>-related segmental overgrowth includes bilateral dysplastic megalencephaly, hemimegalencephaly and focal cortical dysplasia, the most common cause of intractable pediatric epilepsy. We generated mouse models expressing the most common activating <italic>Pik3ca</italic> mutations (<italic>H1047R</italic> and <italic>E545K</italic>) in developing neural progenitors. These accurately recapitulate all the key human pathological features including brain enlargement, cortical malformation, hydrocephalus and epilepsy, with phenotypic severity dependent on the mutant allele and its time of activation. Underlying mechanisms include increased proliferation, cell size and altered white matter. Notably, we demonstrate that acute 1hour-suppression of PI3K signaling despite the ongoing presence of dysplasia has dramatic anti-epileptic benefit. Thus PI3K inhibitors offer a promising new avenue for effective anti-epileptic therapy for intractable pediatric epilepsy patients.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal experimentation done in this study was done in accordance with the guidelines laid down by the Institutional Animal Care and Use Committees (IACUC) of Seattle Children's Research Institute, Seattle, WA (protocol 14208), St. Jude Children's Research Hospital, Memphis, TN (protocol 278), Dana Farber Cancer Institute, Boston, MA (protocol 06-034).</p></fn></fn-group></back></article>